News: Covidien PLC (COV.F)
49.01EUR
8:41am EDT
€-0.14 (-0.28%)
€50.21
€49.08
€49.08
€48.93
65
147
€53.58
€41.23
Wed, Dec 26 2012
Covidien to acquire CV Ingenuity
- Medical device and products maker Covidien Plc on Wednesday said it has a definitive agreement to acquire CV Ingenuity, a privately-held company focusing on treatments for peripheral arterial disease.
Press Releases
- Covidien plc to Report Third-Quarter Results on August 1, 2013
- Covidien Announces Publication of Final Results of Pipeline™ Embolization Device Pivotal Study
- Covidien Announces Effectiveness of Mallinckrodt Form 10 Registration Statement
- Next-Generation Clot Retrieval Technology Improves Patient Outcomes vs. First-Generation Devices, Say Leading Stroke Physicians
- Covidien and Mallinckrodt to Present at Goldman Sachs Conference
- Covidien Nellcor™ Pulse Oximeters Receive FDA 510(k) Clearance with Labeling for Use in Newborn Screening for Critical Congenital Heart Disease
- Covidien Board of Directors Approves Separation of Pharmaceuticals Business and Declares Dividend of Mallinckrodt Ordinary Shares
- Covidien and Mallinckrodt to Present at Deutsche Bank Conference
- Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression
- Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
